New drug OM336 aims to tame overactive immune system
Disease control
Recruiting now
This early-phase trial tests a new drug called OM336 in 32 adults with autoimmune cytopenias, conditions where the immune system attacks blood cells. The study focuses on safety and how the drug moves through the body, not yet on curing the disease. Participants must have tried a…
Phase: PHASE1 • Sponsor: Lakefront Biotherapeutics West LLC • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC